Business
Spectral'S Endotoxin Activity Assay (EAA(TM)) Systems placed in Italy
Spectral'S Endotoxin Activity Assay (EAA(TM)) Systems placed in Italy.
About this update from Spectral Medical Inc
[{"type":"text","content":"\n\n\n\n\nTORONTO, July 11 /CNW/ - Spectral Diagnostics Inc. (\"Spectral\"), today\nannounced the commercial placement of their proprietary sepsis assay system\n(\"EAA(TM)\") in two of Italy's largest hospitals though Estor S.p.A. (\"Estor\"),\na major distributor of medical products in Italy. These systems measure\ncirculating Endotoxin in patients and give accurate results in less than 30\nminutes, enabling rapid initiation of appropriate treatment, and monitoring of\nits effectiveness.\n\nEstor was established on May 1, 1999 as a spin-off of the Hospital Supply\nDivision of Aventis (ex-Hoechst). The sales team has been operating in the\nfields of Dialysis since 1980, Interventional Cardiology since 1990 and ICU\nfrom 1999, distributing unique and innovative products such as Toray PMMA\nbased dialysers, and the Toray Endotoxin absorption cartridge (\"Toraymyxin\").\n\n\"We are very pleased to see this uptake of the EAA(TM). Estor is an\nexperienced and knowledgeable distributor of products, using a 'theranostics\napproach', aimed at reducing the impact of sepsis,\" stated Dr. Paul Walker,\nPresident & CEO of Spectral. \"This early adoption of equipment and tests for\nthe EAA(TM) in Italy should lead to increased revenue in the latter part of\nour current fiscal year.\" added Dr. Walker.\n\n\"Estor has been engaged in the promotion of Toraymyxin, the cartridge for\nextracorporeal removal of Endotoxin, for more than 4 years treating more than\n1000 patients in Italy. We now have the appropriate diagnostic tool for\ndetecting Endotoxemia and properly selecting patients for the use of\nToraymyxin. We strongly believe that the association between EAA(TM) and\nToraymyxin could represent a revolution in the management of septic shock,\"\ncommented Dr. Federico D'Avanzo, President of Estor.\n\nSpectral is a developer of innovative technologies for comprehensive\ndisease management. Spectral provides accurate and timely information to\nclinicians enabling the early initiation of appropriate and targeted therapy.\nCurrent products include Spectral's rapid West Nile Virus assay and its FDA\napproved rapid diagnostic for sepsis, the EAA(TM), as well as a range of other\nbiological reagents. Spectral's common shares are listed on The Toronto Stock\nExchange: SDI.\n\nInformation in this news release that is not current or historically\n...